Ubiquitination of p53 at multiple sites in the DNA-binding domain

Molecular Cancer Research

Volumn 4, Issue 1, 2006, Pages 15-25

  Chan, Wan Mui ^a   Mak, Man Chi ^a   Fung, Tsz Kan ^a   Lau, Anita ^a   Siu, Wai Yi ^a   Poon, Randy Y C ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

BINDING SITES; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; HUMANS; LYSINE; MUTATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS; VIRAL PROTEINS;

EID: 32944458404     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0097     Document Type: Article

References (44)

1. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003;21:313-20.
2. Hollstein M, Shomer B, Greenblatt M, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
3. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
4. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.
5. Harper JW. Neddylating the guardian: Mdm2 catalyzed conjugation of Nedd8 to p53. Cell 2004;118:2-4.
6. Vargas DA, Takahashi S, Ronai Z. Mdm2: a regulator of cell growth and death. Adv Cancer Res 2003;89:1-34.
7. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
8. Gu J, Nie L, Wiederscham D, Yuan ZM. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol Cell Biol 2001;21:8533-46.
9. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001;21:8521-32.
10. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003;302:1972-5.
11. Grossman SR, Deato ME, Brignone C, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003;300:342-4.
12. Sui G, Affar el B, Shi Y, et al. Yin yang 1 is a negative regulator of p53. Cell 2004;117:859-72.
13. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-6.
14. Badciong JC, Haas AL. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002;277:49668-75.
15. Doman D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
16. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-91.
17. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991;10:4129-35.
18. King RW, Glotzer M, Kirschner MW. Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates. Mol Biol Cell 1996;7:1343-57.
19. Taniguchi T, Garcia-Higuera I, Xu B, et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002;109:459-72.
20. Petroski MD, Deshaies RJ. Context of multiubiquitin chain attachment influences the rate of Sic1 degradation. Mol Cell 2003;11:1435-44.
21. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002;277:50607-11.
22. Gostissa M, Hengstermann A, Fogal V, et al. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J 1999;18:6462-71.
23. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999;18:6455-61.
24. Nakamura S, Roth JA, Mukhopadhyay T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 2000;20:9391-8.
25. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000;20:8458-67.
26. Camus S, Higgins M, Lane DP, Lain S. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett 2003;536:220-4.
27. Krummel KA, Lee CJ, Toledo F, Wahl GM. The C-terminal lysines fine-tune p53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A 2005;102:10188-93.
28. Crook T, Ludwig RL, Marston NJ, Willkomm D, Vousden KH. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology 1996;217:285-92.
29. Fung TK, Yam CH, Poon RYC. The N-terminal regulatory domain of cyclin A contains redundant ubiquitination targeting sequences and acceptor sites. Cell Cycle 2005;4:1411-20.
30. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004;118:83-97.
31. Sakaguchi K, Herrera JE, Saito S, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998;12:2831-41.
32. Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-9.
33. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997;90:595-606.
34. Mansur CP, Marcus B, Dalal S, Androphy EJ. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 1995;10:457-65.
35. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-53.
36. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003;115:71-82.
37. Leung KM, Po LS, Tsang FC, et al. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res 2002;62:4890-3.
38. 2-M by mechanisms fundamentally different from other cyclins. J Biol Chem 2002;277:35140-9.
39. Chan WM, Siu WY, Lau A, Poon RYC. How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 2004;24:3536-51.
40. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743-9.
41. Ausubel F, Brent R, Kingston R, et al. Current protocols in molecular biology. New York: John Wiley & Sons; 1991.
42. Poon RYC, Toyoshima H, Hunter T. Redistribution of the CDK inhibitor p27 between different cyclin CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995;6:1197-213.
43. Yam CH, Siu WY, Lau A, Poon RYC. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J Biol Chem 2000;275:3158-67.
44. Ongkeko WM, Wang XQ, Siu WY, et al. MDM2 and MDMX bind and stabilize the tumor suppressor p53-related protein p73. Curr Biol 1999;9:829-32.